Category - Feature

Feature

International Stem Cell scores neuronal goal in treating Parkinson’s

By Len Zehr Positive animal data reported by International Stem Cell (OTCBB:ISCO) last month brings the company one step closer to starting human testing of its stem cell technology to treat Parkinson’s disease. “We...

April 2, 2013

Feature

OncoGenex’s OGX-427 drug gaining investor attention

By Len Zehr Even though OncoGenex Pharmaceuticals (NASDAQ:OGXI) and its pivotal programs with lead oncology candidate, custirsen, are being closely followed, investors are beginning to notice the company’s second...

March 26, 2013

Feature

Sucampo sees revenue from three continents by year end

By Len Zehr Sucampo Pharmaceuticals (NASDAQ:SCMP) expects to be generating revenue from three continents – North America, Europe and Asia – by the end of 2013 from its two approved prostones products, Amitiza for...

March 19, 2013

Feature

DURECT awaiting Pfizer meeting with FDA on Remoxy

By Len Zehr DURECT (NASDAQ:DRRX) has a lot riding on a meeting in late March between its marketing partner, Pfizer, and the FDA to discuss resubmitting a new drug application for its lead pain drug, Remoxy, as a tamper...

February 26, 2013

Feature

In conversation with Will Zerhouni

By Len Zehr As CEO of closely held i3 Analytics, Will Zerhouni founded the company on the belief that data analytics should be for everyone in biopharma, not just major players with deep pockets. As a former associate...

February 5, 2013

Feature

Prima BioMed to get key CVac data in second half

By Len Zehr After posting positive trends in interim data, Prima BioMed (ASX:PRR; NASDAQ:PBMD; ISIN:US74154B2034) is focusing on two final data readouts in the second half this year from a Phase 2b clinical trial of its...

January 29, 2013

Feature

Trimel in pre-NDA meeting with FDA next month

By Len Zehr Fresh from reporting positive Phase 3 results for its CompleoTRT intranasal gel for “Low T”, Trimel Pharmaceutics (TSX:TRL) plans to meet with the FDA in February to discuss its plans for filing a new drug...

January 15, 2013

Category - Feature

International Stem Cell scores neuronal goal in treating Parkinson’s

OncoGenex’s OGX-427 drug gaining investor attention

Sucampo sees revenue from three continents by year end

DURECT awaiting Pfizer meeting with FDA on Remoxy

In conversation with Will Zerhouni

Prima BioMed to get key CVac data in second half

Trimel in pre-NDA meeting with FDA next month

General

More